Noninvasive placement and activation of deep-brain stimulating magnetic particles for reduction of drug-seeking behaviors

Information

  • Research Project
  • 9465717
  • ApplicationId
    9465717
  • Core Project Number
    R41DA045398
  • Full Project Number
    1R41DA045398-01
  • Serial Number
    045398
  • FOA Number
    PA-16-303
  • Sub Project Id
  • Project Start Date
    3/1/2018 - 6 years ago
  • Project End Date
    2/28/2019 - 5 years ago
  • Program Officer Name
    BOUGH, KRISTOPHER J
  • Budget Start Date
    3/1/2018 - 6 years ago
  • Budget End Date
    2/28/2019 - 5 years ago
  • Fiscal Year
    2018
  • Support Year
    01
  • Suffix
  • Award Notice Date
    2/20/2018 - 6 years ago

Noninvasive placement and activation of deep-brain stimulating magnetic particles for reduction of drug-seeking behaviors

Abstract Deep brain stimulation (DBS) with implantable electrodes has been used for reduction of ethanol abuse and drug-seeking behaviors in Europe [1?4]. The use of such deep-brain stimulation procedures has been problematic because of concerns about invasiveness of the procedure. Applicant has developed a new noninvasive method of transporting magnetic particles directly to target sites within the brain. We propose to use this method to place magnetic particles in brain locations where DBS studies have shown reductions in drug-seeking behavior. Once placed, the magnetic particles can be activated through external application of magnetic fields to stimulate neurons mechanically. When translated into clinical use, magnetic activation could be performed with a wearable device, as has been done for other neurological conditions (migraine, epilepsy). The particles are designed to degrade over a pre-selected time interval (e.g., six-months). In this proposal, we will demonstrate the short-term safety and efficacy of the construct in an rodent model of opiate relapse after a period of abstinence. Efficacy will be measured by quantifying reinstatement of drug-seeking behavior. The results of this collaborative work will lay the foundation for Phase II studies, which will provide information needed for human trials.

IC Name
NATIONAL INSTITUTE ON DRUG ABUSE
  • Activity
    R41
  • Administering IC
    DA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    229701
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    279
  • Ed Inst. Type
  • Funding ICs
    NIDA:229701\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    WEINBERG MEDICAL PHYSICS, LLC
  • Organization Department
  • Organization DUNS
    809594661
  • Organization City
    NORTH BETHESDA
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    208521708
  • Organization District
    UNITED STATES